The Clinical Approach to Lung Disease in Patients with Cystic Fibrosis

被引:24
|
作者
O'Sullivan, Brian P. [1 ]
Flume, Patrick [2 ]
机构
[1] Univ Massachusetts, Sch Med, Dept Pediat, UMass Mem Med Ctr, Worcester, MA 01655 USA
[2] Med Coll S Carolina, Dept Med, Div Pulm Crit Care Allergy & Sleep Med, Charleston, SC USA
关键词
Cystic fibrosis; inflammation; antibiotic therapy; treatment; prophylaxis; pathogenesis; PSEUDOMONAS-AERUGINOSA INFECTION; ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; RANDOMIZED CONTROLLED-TRIAL; HIGH-DOSE IBUPROFEN; INTRAVENOUS ANTIBIOTIC-TREATMENT; RESISTANT STAPHYLOCOCCUS-AUREUS; INHALED HYPERTONIC SALINE; PLACEBO-CONTROLLED TRIAL; RECOMBINANT HUMAN DNASE; ACTING BETA-AGONISTS;
D O I
10.1055/s-0029-1238909
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
There is strong evidence that early, aggressive therapy of lung disease leads to improved quality and quantity of life for patients with cystic fibrosis (CF). The treatment of pulmonary disease associated with CF is multifactorial, encompassing prophylaxis, aggressive treatment of infection, use of antiinflammatory agents, and treatment of severe complications. Chest physiotherapy on a regular basis, perhaps using new modalities that allow patient autonomy, is also crucial. This review covers the pathogenesis of CF lung disease and current approaches to therapy, highlighting guidelines recently published by the Cystic Fibrosis Foundation. Clinicians caring for patients with CF should maximize current therapies with the goal of preserving lung function until the time a more definitive curative or controller medication is developed. Empowering patients in the process of providing their own care is a key to achieving this goal.
引用
收藏
页码:505 / 513
页数:9
相关论文
共 50 条
  • [41] Cystic fibrosis lung disease: Current perspectives
    Jung, Jin-A
    ALLERGY ASTHMA & RESPIRATORY DISEASE, 2020, 8 (01): : 3 - 8
  • [42] Antioxidant supplementation for lung disease in cystic fibrosis
    Ciofu, Oana
    Smith, Sherie
    Lykkesfeldt, Jens
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2019, (10):
  • [43] Role of corticosteroids in cystic fibrosis lung disease
    BalfourLynn, IM
    Dinwiddie, R
    JOURNAL OF THE ROYAL SOCIETY OF MEDICINE, 1996, 89 : 8 - 13
  • [44] Genetic therapies for cystic fibrosis lung disease
    Sinn, Patrick L.
    Anthony, Reshma M.
    McCray, Paul B., Jr.
    HUMAN MOLECULAR GENETICS, 2011, 20 : R79 - R86
  • [45] Update on pathogenesis of cystic fibrosis lung disease
    Donaldson, SH
    Boucher, RC
    CURRENT OPINION IN PULMONARY MEDICINE, 2003, 9 (06) : 486 - 491
  • [46] Emerging therapies for cystic fibrosis lung disease
    Grasemann, Hartmut
    Ratjen, Felix
    EXPERT OPINION ON EMERGING DRUGS, 2010, 15 (04) : 653 - 659
  • [47] An overview of the pathogenesis of cystic fibrosis lung disease
    Boucher, RC
    ADVANCED DRUG DELIVERY REVIEWS, 2002, 54 (11) : 1359 - 1371
  • [48] Emerging therapies for cystic fibrosis lung disease
    Rubin, BK
    CHEST, 1999, 115 (04) : 1120 - 1126
  • [49] PERFUSION MRI IN CYSTIC FIBROSIS LUNG DISEASE
    Wielpuetz, Mark O.
    PEDIATRIC PULMONOLOGY, 2017, 52 : S204 - S204
  • [50] Antioxidant supplementation for lung disease in cystic fibrosis
    Ciofu, Oana
    Lykkesfeldt, Jens
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2014, (08):